Mendjargal, Adilsaikhan
Loading...
Товч нэр
Mendjargal, Adilsaikhan
Бүтэн нэр
Mendjargal Adilsaikhan
Латин нэр
Mendjargal Adilsaikhan
Албан тушаал
Судлаач
ORCID
4 results
Now showing 1 - 4 of 4
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prevalence of viral infection and its impact on early-stage hepatocellular carcinoma: Insights from Mongolia, a developing country(Elsevier BV, 2026-07-30); ; ; Yumchinserchin Narangerel, Tsendjav Tsogtbaatar, Gonchigsuren Dagvasumberel, Dashkhorol Davaadorj, Enebish Sundui and Adilsaikhan Mendjargal. Int J Gastrointest Interv -0001;0:. https://doi.org/10.18528/ijgii260007 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Variables Influencing 6-Month Relapse in Early-Stage Hepatocellular Carcinoma After Radiofrequency Ablation(Mongolian National University of Medical Sciences, 2024-03-12); ; ; Objectives: Hepatocellular carcinoma (HCC) emerged as a global health concern in 2020, ranking as the sixth most diagnosed cancer and the third leading cause of cancer-related death. This study analyzed predictors of 6-month relapse in early-stage HCC patients after Radiofrequency Ablation (RFA). Methods: This retrospective study, from January 1, 2018, to December 31, 2022, meticulously explored ablation methods for early-stage HCC treatment. Data collection included a 6-month relapse definition, demographic details, and tumor-related variables. Results: Over five years, 483 participants underwent RFA for early-stage HCC, presenting diverse demographic and tumor-related profiles. Significant associations were found between relapse and factors such as gender, smoking, alcohol use, tumor size, specific tumor locations, and pre-treatment AST levels. Notably, 6.8% of participants experienced relapse within six months. In the multivariate analysis, adjusting for confounders, smoking (p = 0.014), tumor size > 3cm (p < 0.001), tumor location S2 (p < 0.001), and pre-treatment AST levels (p = 0.015) remained significant predictors. Conclusion: This study sheds light on the complex dynamics of 6-month relapse in early-stage HCC patients, emphasizing the significance of predictors such as smoking, tumor size, tumor location, and pre-treatment AST levels. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison of Clinical Features of Hepatitis B and C Virus-Related Hepatocellular Carcinoma(Mongolian National University of Medical Sciences, 2022-09-30); ; ; Objective: To compare the clinical characteristics of hepatitis B virus-related hepatocellular carcinoma (HBV group) and C virus-related hepatocellular carcinoma (HCV group). Methods: By a single century, we analyzed the clinical characteristics of 23 patients with hepatitis B virus-related hepatocellular carcinoma (HBV group) and 34 with hepatitis C virus-related hepatocellular carcinoma (HCV group). Results: The patients in the HBV group (mean age 61.1 year) were about 6 years younger than those in the HCV group (mean age 67.1 year). Liver function, as measured by indocyanine green retention at 15 min, was better in the HBV group (17.5 %) than in the HCV group (25.4 %). A higher proportion of the HBV group (55 %) than the HCV group (44 %) had clinical stage I. T-factor differed significantly between the groups: 53 % of the HBV group were T3 - 4 compared with 41 % of the HCV group. Furthermore, a higher proportion of the HBV group was graded 2 - 3 for tumor thrombus in the portal vein (20.3 %) and had poorly differentiated hepatocellular carcinoma (7 %) compared with the HCV group (7.1 % and 5 % respectively). Univariate analysis identified poor prognostic factors for hepatocellular carcinoma as HBV, age < or = 50 year, clinical stage II-III, a high AFP level, higher number of tumors, larger tumor size, tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3. On multivariate analysis, poor prognostic factors were a high AFP level, a higher number of tumors, and tumor thrombus in the portal vein 2 - 3 and in the hepatic vein 2 - 3, but not HBV, age, clinical stage, or tumor size. In the multiple logistic regression models on the hepatitis infection, the OR for ASAT was 2.01 (95 % CI 1.41 - 6.91), statistically significant (p < 0.05). Conclusion: These results suggest that HBV itself is not a stronger prognostic factor than HCV. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Histopathological Features of Hepatocellular Carcinoma in Patients with Hepatitis B and D Virus Infection: A Single-Institution Study in Mongolia(MDPI AG, 2025-01)Scopus© Citations 1